These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22910968)

  • 1. Relationships between in vitro drug dissolution and in vivo response.
    Langguth P; Marroum P
    Biopharm Drug Dispos; 2012 Oct; 33(7):347-8. PubMed ID: 22910968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC).
    Hayes S; Dunne A; Smart T; Davis J
    J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe.
    Limberg J; Potthast H
    Biopharm Drug Dispos; 2013 Jul; 34(5):247-53. PubMed ID: 23585295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative and generalized approach to in vitro-in vivo correlation.
    Vitková Z; Vitko A; Zabka M; Cizmárik J
    Acta Pol Pharm; 2011; 68(3):417-21. PubMed ID: 21648197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
    Mishra V; Gupta U; Jain NK
    Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
    Schnieders B
    Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches for the development of solid and semi-solid lipid-based formulations.
    Jannin V; Musakhanian J; Marchaud D
    Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
    Chen ML
    Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
    Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
    Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.
    Vasconcelos T; Sarmento B; Costa P
    Drug Discov Today; 2007 Dec; 12(23-24):1068-75. PubMed ID: 18061887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissolution testing of oral modified-release dosage forms.
    Garbacz G; Klein S
    J Pharm Pharmacol; 2012 Jul; 64(7):944-68. PubMed ID: 22686342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioequivalence in vitro evaluation of some antibacterial generic dosage forms].
    Semdé R; Ouédraogo HW; Guissou IP; Amighi K
    J Pharm Belg; 2005; 60(2):51-5. PubMed ID: 16035369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.